메뉴 건너뛰기




Volumn 38, Issue 6, 2011, Pages 765-769

Changes: Choosing a target?

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 3 METHYLSPIPERONE C 11; 3 QUINUCLIDINYL 4 IODOBENZILATE I 123; 6 FLUORODOPAMINE F 18; ARSPHENAMINE; BCR ABL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; GADOLINIUM DOTA C HF GA 68; IMATINIB; IODINE 131; RADIOPHARMACEUTICAL AGENT; TANESPIMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

EID: 80051683608     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.12.010     Document Type: Editorial
Times cited : (2)

References (29)
  • 1
    • 84855652248 scopus 로고    scopus 로고
    • http://www.en.wikiquote.org/wiki/Charles_Darwin.
  • 2
    • 0035063889 scopus 로고    scopus 로고
    • Molecular imaging
    • Weissleder R., Mahmood U. Molecular imaging. Radiology 2001, 219(2):316-333.
    • (2001) Radiology , vol.219 , Issue.2 , pp. 316-333
    • Weissleder, R.1    Mahmood, U.2
  • 3
    • 66049122599 scopus 로고    scopus 로고
    • Hybrid imaging (SPECT/CT and PET/CT)-improving the diagnostic accuracy of functional/metabolic and anatomic imaging
    • Even-Sapir E., Keidar Z., Bar-Shalom R. Hybrid imaging (SPECT/CT and PET/CT)-improving the diagnostic accuracy of functional/metabolic and anatomic imaging. Semin Nucl Med 2009, 39(4):264-275.
    • (2009) Semin Nucl Med , vol.39 , Issue.4 , pp. 264-275
    • Even-Sapir, E.1    Keidar, Z.2    Bar-Shalom, R.3
  • 4
    • 27744562616 scopus 로고    scopus 로고
    • Joint SNM/RSNA Molecular Imaging Summit Statement. SNM; Radiological Society of North America (RSNA). J Nucl Med. Sep;46(9):11N-13N, 42N.
    • Thakur ML, Lentle BC. Joint SNM/RSNA Molecular Imaging Summit Statement. SNM; Radiological Society of North America (RSNA). J Nucl Med. 2005 Sep;46(9):11N-13N, 42N.
    • (2005)
    • Thakur, M.L.1    Lentle, B.C.2
  • 5
    • 12444273887 scopus 로고    scopus 로고
    • Mechanism of target specific uptake
    • John Wiley and Sons, Ltd, West Sussex, England, J.W. Michael, C. Redvanly (Eds.)
    • Eckelman W.C. Mechanism of target specific uptake. Handbook of radiopharmaceuticals: radiochemistry and applications 2003, 487-500. John Wiley and Sons, Ltd, West Sussex, England. J.W. Michael, C. Redvanly (Eds.).
    • (2003) Handbook of radiopharmaceuticals: radiochemistry and applications , pp. 487-500
    • Eckelman, W.C.1
  • 8
    • 63849316541 scopus 로고    scopus 로고
    • Organofluorosilanes as model compounds for 18F-labeled silicon-based PET tracers and their hydrolytic stability: experimental data and theoretical calculations (PET = positron emission tomography)
    • Höhne A., Yu L., Mu L., Reiher M., Voigtmann U., Klar U., Graham K., Schubiger P.A., Ametamey S.M. Organofluorosilanes as model compounds for 18F-labeled silicon-based PET tracers and their hydrolytic stability: experimental data and theoretical calculations (PET = positron emission tomography). Chemistry 2009, 15(15):3736-3743.
    • (2009) Chemistry , vol.15 , Issue.15 , pp. 3736-3743
    • Höhne, A.1    Yu, L.2    Mu, L.3    Reiher, M.4    Voigtmann, U.5    Klar, U.6    Graham, K.7    Schubiger, P.A.8    Ametamey, S.M.9
  • 9
    • 84878624336 scopus 로고    scopus 로고
    • Servizi Grafica Editoriali snc, Padova Italy, U. Mazzi, W.C. Eckelman, W.A. Volkert (Eds.)
    • Technetium and other radiometals in chemistry and medicine 2010, 3-143. Servizi Grafica Editoriali snc, Padova Italy. U. Mazzi, W.C. Eckelman, W.A. Volkert (Eds.).
    • (2010) Technetium and other radiometals in chemistry and medicine , pp. 3-143
  • 11
    • 0842304962 scopus 로고    scopus 로고
    • Streamlining drug development: finding the right drug against the right target to treat the right disease
    • Ng J.H., Ilag L.L. Streamlining drug development: finding the right drug against the right target to treat the right disease. Drug Discov Today 2004, 9:59.
    • (2004) Drug Discov Today , vol.9 , pp. 59
    • Ng, J.H.1    Ilag, L.L.2
  • 12
    • 77956474288 scopus 로고    scopus 로고
    • Do technical and commercial biases contribute to the pharmaceutical industry's productivity problems? An analysis of how reordering priorities can improve productivity
    • Fryburg D.A. Do technical and commercial biases contribute to the pharmaceutical industry's productivity problems? An analysis of how reordering priorities can improve productivity. Drug Discovery Today 2010, 15:766-772.
    • (2010) Drug Discovery Today , vol.15 , pp. 766-772
    • Fryburg, D.A.1
  • 13
    • 51249087509 scopus 로고    scopus 로고
    • Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine
    • Eckelman W.C., Reba R.C., Kelloff G.J. Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. Drug Discov Today 2008, 13(17-18):748-759.
    • (2008) Drug Discov Today , vol.13 , Issue.17-18 , pp. 748-759
    • Eckelman, W.C.1    Reba, R.C.2    Kelloff, G.J.3
  • 14
    • 0345999007 scopus 로고    scopus 로고
    • Labeled agents as tracers and carriers: theory and practice
    • Published By Springer Verlag, Germany, L.E. Feinendegen, W.W. Shreeve, W.C. Eckelman, Y.W. Bahk, H.N. Wagner (Eds.)
    • Eckelman W.C. Labeled agents as tracers and carriers: theory and practice. For "Molecular nuclear medicine: the challenge from the human genome" 2003, 85-98. Published By Springer Verlag, Germany. L.E. Feinendegen, W.W. Shreeve, W.C. Eckelman, Y.W. Bahk, H.N. Wagner (Eds.).
    • (2003) For "Molecular nuclear medicine: the challenge from the human genome" , pp. 85-98
    • Eckelman, W.C.1
  • 15
    • 32244440536 scopus 로고    scopus 로고
    • The use of genetic SNPs as new diagnostic markers in preventive medicine
    • Cantor C.R. The use of genetic SNPs as new diagnostic markers in preventive medicine. Ann. N. Y. Acad. Sci 2005, 1055:48-57.
    • (2005) Ann. N. Y. Acad. Sci , vol.1055 , pp. 48-57
    • Cantor, C.R.1
  • 17
    • 0041984595 scopus 로고    scopus 로고
    • 8FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec)
    • Stroobants S., Goeminne J., Seegers M., et al. 8FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003, 39:2012-2020.
    • (2003) Eur J Cancer , vol.39 , pp. 2012-2020
    • Stroobants, S.1    Goeminne, J.2    Seegers, M.3
  • 19
    • 49049095039 scopus 로고    scopus 로고
    • Metaiodobenzylguanidine in the diagnosis and therapy of neuroendocrine tumors
    • Coleman R.E. Metaiodobenzylguanidine in the diagnosis and therapy of neuroendocrine tumors. Nucl Med Biol 2008, 35:S1:1.
    • (2008) Nucl Med Biol , vol.35
    • Coleman, R.E.1
  • 20
    • 34848871896 scopus 로고    scopus 로고
    • (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization
    • Vallabhajosula S. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med 2007, 37(6):400-419.
    • (2007) Semin Nucl Med , vol.37 , Issue.6 , pp. 400-419
    • Vallabhajosula, S.1
  • 22
    • 0027433206 scopus 로고
    • Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327
    • Fowler J.S., Volkow N.D., Logan J., Schlyer D.J., MacGregor R.R., Wang G.J., Wolf A.P., Pappas N., Alexoff D., Shea C., et al. Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327. Neurology 1993, 43(10):1984-1992.
    • (1993) Neurology , vol.43 , Issue.10 , pp. 1984-1992
    • Fowler, J.S.1    Volkow, N.D.2    Logan, J.3    Schlyer, D.J.4    MacGregor, R.R.5    Wang, G.J.6    Wolf, A.P.7    Pappas, N.8    Alexoff, D.9    Shea, C.10
  • 24
    • 77950579860 scopus 로고    scopus 로고
    • Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons
    • Liu L., Xu Y., Shea C., Fowler J.S., Hooker J.M., Tonge P.J. Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons. J Med Chem 2010, 53(7):2882-2891.
    • (2010) J Med Chem , vol.53 , Issue.7 , pp. 2882-2891
    • Liu, L.1    Xu, Y.2    Shea, C.3    Fowler, J.S.4    Hooker, J.M.5    Tonge, P.J.6
  • 25
    • 34548568292 scopus 로고    scopus 로고
    • The black swan: the impact of the highly improbable. Random House Inc., New York
    • Taleb N.N. The black swan: the impact of the highly improbable. Random House Inc., New York. NY 2007, 366.
    • (2007) NY , pp. 366
    • Taleb, N.N.1
  • 26
    • 84855696992 scopus 로고    scopus 로고
    • Validated on 10/19/2010.
    • Validated on 10/19/2010. http://www.interactive.snm.org/index.cfm?PageID=1107.
  • 28
    • 70349956433 scopus 로고    scopus 로고
    • Finding the missing heritability of complex diseases
    • PMID: 19812666 [PubMed-indexed for MEDLINE]
    • Manolio T.A., Collins F.S., Cox N.J., et al. Finding the missing heritability of complex diseases. Nature 2009, 461(7265):747-753. PMID: 19812666 [PubMed-indexed for MEDLINE].
    • (2009) Nature , vol.461 , Issue.7265 , pp. 747-753
    • Manolio, T.A.1    Collins, F.S.2    Cox, N.J.3
  • 29
    • 77951468653 scopus 로고    scopus 로고
    • The Gene, Environment Association Studies Consortium (GENEVA): maximizing the knowledge obtained from GWAS by collaboration across studies of multiple conditions
    • PMCID: PMC2860056; NIHMSID: NIHMS176834
    • Cornelis M.C., Agrawal A., Cole J.W., et al. The Gene, Environment Association Studies Consortium (GENEVA): maximizing the knowledge obtained from GWAS by collaboration across studies of multiple conditions. Genet Epidemiol 2010, 34(4):364-372. PMCID: PMC2860056; NIHMSID: NIHMS176834.
    • (2010) Genet Epidemiol , vol.34 , Issue.4 , pp. 364-372
    • Cornelis, M.C.1    Agrawal, A.2    Cole, J.W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.